Diagnostic and prognostic biomarkers for the screening of patients with metabolic liver disease risk.
作者信息
Munteanu Mona
出版信息
Germs. 2018 Dec 3;8(4):175-177. doi: 10.18683/germs.2018.1150. eCollection 2018 Dec.
Abstract
摘要
相似文献
1
Diagnostic and prognostic biomarkers for the screening of patients with metabolic liver disease risk.用于筛查代谢性肝病风险患者的诊断和预后生物标志物。
Germs. 2018 Dec 3;8(4):175-177. doi: 10.18683/germs.2018.1150. eCollection 2018 Dec.
2
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.酒精性肝病患者纤维化非侵入性生物标志物的诊断和预后价值
Hepatology. 2009 Jan;49(1):97-105. doi: 10.1002/hep.22576.
3
The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation.糖组学作为肝病和肝移植预后生物标志物的潜力。
Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):309-313.
4
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.非酒精性脂肪性肝病中的肝纤维化——具有预后意义的诊断挑战
World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077.
5
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.通过泛癌筛选发现肾透明细胞癌生存时间的独特蛋白表达特征。
BMC Genomics. 2017 Oct 3;18(Suppl 6):678. doi: 10.1186/s12864-017-4026-6.
6
Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma.肝细胞癌新型诊断和预后DNA甲基化特征的构建与验证
Front Genet. 2020 Aug 13;11:906. doi: 10.3389/fgene.2020.00906. eCollection 2020.
7
Metabolic rearrangements in primary liver cancers: cause and consequences.原发性肝癌中的代谢重排：原因与后果。
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):748-766. doi: 10.1038/s41575-019-0217-8. Epub 2019 Oct 30.
8
Nonalcoholic fatty liver disease: Evolving paradigms.非酒精性脂肪性肝病：不断变化的范式。
World J Gastroenterol. 2017 Sep 28;23(36):6571-6592. doi: 10.3748/wjg.v23.i36.6571.
9
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.肝纤维化和脂肪变性生物标志物在 2 型糖尿病和血脂异常中的预后价值。
Aliment Pharmacol Ther. 2014 Nov;40(9):1081-93. doi: 10.1111/apt.12946. Epub 2014 Sep 3.
10
Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review.通过质谱法发现的非酒精性脂肪性肝病（脂肪变性和非酒精性脂肪性肝炎）的候选蛋白质组学生物标志物：一项系统综述。
Biomarkers. 2016;21(2):102-14. doi: 10.3109/1354750X.2015.1118542. Epub 2015 Dec 3.
本文引用的文献
1
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.非酒精性脂肪性肝病患者 FibroTest 的长期预后价值，与慢性丙型、乙型和酒精性肝病相比。
Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17.
2
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的无创性生物标志物：当前进展与未来前景。
Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):461-478. doi: 10.1038/s41575-018-0014-9.
3
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.使用简化组织学参考标准的非酒精性脂肪性肝炎新型非侵入性检测方法的诊断性能
Eur J Gastroenterol Hepatol. 2018 May;30(5):569-577. doi: 10.1097/MEG.0000000000001064.
4
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.增强型肝纤维化试验与 FibroTest、瞬时弹性成像和间接标志物在诊断酒精性肝病患者中晚期纤维化的准确性比较。
Gastroenterology. 2018 Apr;154(5):1369-1379. doi: 10.1053/j.gastro.2018.01.005. Epub 2018 Jan 6.
5
Impact of steatosis and inflammation definitions on the performance of NASH tests.脂肪变性和炎症定义对非酒精性脂肪性肝炎检测性能的影响。
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):384-391. doi: 10.1097/MEG.0000000000001033.
6
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
7
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中血液纤维化检测和 FibroScan 肝硬度测量的诊断准确性和预后意义。
J Hepatol. 2016 Sep;65(3):570-8. doi: 10.1016/j.jhep.2016.04.023. Epub 2016 May 2.
8
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.
9
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.系统评价与荟萃分析：慢性丙型和乙型肝炎纤维化诊断生物标志物的直接比较
Aliment Pharmacol Ther. 2016 Jan;43(1):16-29. doi: 10.1111/apt.13446. Epub 2015 Oct 30.
10
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.肝纤维化和脂肪变性生物标志物在 2 型糖尿病和血脂异常中的预后价值。
Aliment Pharmacol Ther. 2014 Nov;40(9):1081-93. doi: 10.1111/apt.12946. Epub 2014 Sep 3.
Zotero 插件